Marx N, Husain M, Lehrke M, Verma S, Sattar N (2022) GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes
A quality multivitamin can help fill common gaps and support energy, recovery, and metabolic health
Clinical trials have shown significant weight loss (up to 24%) and improvements in glycemic control, liver fat, and insulin sensitivity, offering a comprehensive approach to obesity and type 2 diabetes management
JAMA Dermatology, 158 (3), 266
Zepbound is a newer drug with less clinical evidence available, while semaglutide GLP-1 remains a tried-and-true alternative because of its track record for weight loss success
There are many semaglutide drugs and GLP-1 agonists that have been recently covered in the media, but we will only discuss Ozempic in this article